sanofi-aventis Canada Inc.
Registration:
17
of
20
(2023-05-23
to
2023-11-24)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Negotiate the listing of Dupixent on the BC PharmaCare formulary
|
Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Health
|
To actively promote the contributions and positive impact of pharmaceutical innovation and the innovative pharmaceutical industry in British Columbia and to increase awareness of the value of innovative therapies on the healthcare system. Ensure any changes to pharmaceutical legislation support appropriate government reimbursement of innovative pharmaceuticals.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|